Skye Bioscience, Inc.
Skye Bioscience, Inc. (SKYE): 2 pipeline candidates · 2 upcoming catalysts · ~6 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
6.0 months
D/E 1.15 · 13% dilution
Lead: Phase 2
2 candidates
2 upcoming, next in ~104d
N/A
A transparent, data-derived signal for Skye Bioscience, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$25.9M
Cash
$8.1M
Quarterly Burn
$8.6M
Runway
6.0 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| nimacimab | Phase 2 |
| sbi-100 ophthalmic emulsion | Phase 2 |
Upcoming Catalysts (2)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
38
Total value held
$3.3M
| Holder | Shares | Value |
|---|---|---|
| baker bros. advisors lp | 1,575,243 | $968K |
| vanguard capital management llc | 1,528,914 | $940K |
| sphera funds management ltd. | 678,928 | $417K |
| blackrock, inc. | 286,131 | $176K |
| geode capital management, llc | 277,256 | $170K |
| millennium management llc | 258,200 | $159K |
| platinum investment management ltd | 233,095 | $143K |
| vanguard fiduciary trust co | 104,229 | $64K |
| citadel advisors llc | 98,900 | $61K |
| state street corp | 75,326 | $46K |
Showing top 10 of 38 institutional holders of Skye Bioscience, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Skye Bioscience, Inc.'s pipeline?
Skye Bioscience, Inc. (SKYE) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Skye Bioscience, Inc.'s lead drug candidate?
Skye Bioscience, Inc.'s most advanced tracked candidate is nimacimab (Phase 2) for Obesity.
What is Skye Bioscience, Inc.'s next catalyst?
Skye Bioscience, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: nimacimab" — expected September 30, 2026.
What is Skye Bioscience, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Skye Bioscience, Inc. has approximately 6.0 months of cash runway.
What is Skye Bioscience, Inc.'s market capitalization?
Skye Bioscience, Inc.'s market capitalization is approximately $25.9M.
Get the full picture on Skye Bioscience, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.